BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25462231)

  • 1. Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
    Stefanachi A; Hanke N; Pisani L; Leonetti F; Nicolotti O; Catto M; Cellamare S; Hartmann RW; Carotti A
    Eur J Med Chem; 2015 Jan; 89():106-14. PubMed ID: 25462231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heteroatom insertion into 3,4-dihydro-1H-quinolin-2-ones leads to potent and selective inhibitors of human and rat aldosterone synthase.
    Grombein CM; Hu Q; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 90():788-96. PubMed ID: 25528333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.
    Yin L; Lucas S; Maurer F; Kazmaier U; Hu Q; Hartmann RW
    J Med Chem; 2012 Jul; 55(14):6629-33. PubMed ID: 22788843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
    Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
    Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
    Gobbi S; Hu Q; Foschi G; Catanzaro E; Belluti F; Rampa A; Fimognari C; Hartmann RW; Bisi A
    Bioorg Chem; 2019 May; 86():401-409. PubMed ID: 30769265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.
    Hu Q; Yin L; Ali A; Cooke AJ; Bennett J; Ratcliffe P; Lo MM; Metzger E; Hoyt S; Hartmann RW
    J Med Chem; 2015 Mar; 58(5):2530-7. PubMed ID: 25711516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors.
    Grombein CM; Hu Q; Heim R; Rau S; Zimmer C; Hartmann RW
    Eur J Med Chem; 2015 Jan; 89():597-605. PubMed ID: 25462268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
    Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
    J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
    Emmerich J; Hu Q; Hanke N; Hartmann RW
    J Med Chem; 2013 Aug; 56(15):6022-32. PubMed ID: 23869452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.
    Hu Q; Kunde J; Hanke N; Hartmann RW
    Eur J Med Chem; 2015; 96():139-50. PubMed ID: 25874338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
    Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
    Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Barassin C; Marchais-Oberwinkler S; Hartmann RW
    J Med Chem; 2005 Oct; 48(21):6632-42. PubMed ID: 16220979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
    Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
    J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent 11β-hydroxylase inhibitors with inverse metabolic stability in human plasma and hepatic S9 fractions to promote wound healing.
    Zhu W; Hu Q; Hanke N; van Koppen CJ; Hartmann RW
    J Med Chem; 2014 Sep; 57(18):7811-7. PubMed ID: 25176013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the fungicide epoxiconazole by virtual screening and biological assessment as inhibitor of human 11β-hydroxylase and aldosterone synthase.
    Akram M; Patt M; Kaserer T; Temml V; Waratchareeyakul W; Kratschmar DV; Haupenthal J; Hartmann RW; Odermatt A; Schuster D
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105358. PubMed ID: 30965118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
    Müller-Vieira U; Angotti M; Hartmann RW
    J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
    Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
    J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of targeting CYP11B.
    Bernhardt R
    Expert Opin Ther Targets; 2016 Aug; 20(8):923-34. PubMed ID: 26854589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.
    Hille UE; Zimmer C; Haupenthal J; Hartmann RW
    ACS Med Chem Lett; 2011 Aug; 2(8):559-64. PubMed ID: 24900349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
    Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
    J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.